A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
Authors: Ashina et al.
Posted in Papers / Classic Papers /
Cephalalgia. 2021 Jan;41(1):33-44. Epub 2020 Nov 24.
PMID: 33231489 | PMCID: PMC7786389 | DOI: 10.1177/0333102420970889
Share this article
Sign Up For An MSC Newsletter
Register to Watch the MSC Emerging Science Contest!
The MSC Emerging Science Contest for Young Investigators will take place on Wednesday, December 13, 2023, from 8-10 PM Eastern (US) time. We welcome those who wish to watch the event as an attendee. Register here to attend, and learn more about the contest here.